

Published in final edited form as:

Nat Genet. 2018 September ; 50(9): 1262–1270. doi:10.1038/s41588-018-0179-8.

Copy-number signatures and mutational processes in ovarian carcinoma

Geoff Macintyre^{1,†}, Teodora E. Goranova^{1,†}, Dilrini De Silva¹, Darren Ennis², Anna M. Piskorz¹, Matthew Eldridge¹, Daoud Sie³, Liz-Anne Lewsley⁴, Aishah Hanif⁴, Cheryl Wilson⁴, Suzanne Dowson², Rosalind M. Glasspool⁵, Michelle Lockley^{6,7}, Elly Brockbank⁸, Ana Montes⁹, Axel Walther¹⁰, Sudha Sundar¹¹, Richard Edmondson^{12,13}, Geoff D. Hall¹⁴, Andrew Clamp¹⁵, Charlie Gourley¹⁶, Marcia Hall¹⁷, Christina Fotopoulou¹⁸, Hani Gabra^{18,19}, James Paul⁴, Anna Supernat¹, David Millan²⁰, Aoisha Hoyle²⁰, Gareth Bryson²⁰, Craig Nourse², Laura Mincarelli², Luis Navarro Sanchez², Bauke Ylstra³, Mercedes Jimenez-Linan²¹, Luiza Moore²¹, Oliver Hofmann^{2,22}, Florian Markowitz^{1,*}, Iain A. McNeish^{2,5,18,*}, and James D. Brenton^{1,21,23,*,#}

¹Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK ²Institute of Cancer Sciences, University of Glasgow, G61 1QH, UK ³VU University Medical Center, Amsterdam 1007 MB, The Netherlands ⁴Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, G12 0YN, UK ⁵Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, UK ⁶Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK ⁷University College London Hospital, London, WC1E 6BD, UK ⁸Barts Health NHS Trust, London,

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

^{*}Co-corresponding authors: Florian Markowitz (Florian.Markowitz@cruk.cam.ac.uk), Iain McNeish (i.mcneish@imperial.ac.uk), James Brenton (James.Brenton@cruk.cam.ac.uk).

[†]These authors contributed equally to this work.

[#]Lead contact

Data Availability

Sequence data that support the findings of this study have been deposited in the European Genome-phenome Archive with the accession code EGAS00001002557. All code required to reproduce the analysis outlined in this manuscript can be found in the following repository (see URL 3).

URLs

Accession Codes
EGAS00001002557

Author contributions

G.M., T.E.G., F.M., I.McN., J.D.B. conceptualized the study; S.D., R.M.G., M.L., E.B., A.M., A.W., S.S., R.E., G.D.H., A.C., C.G., M.H., C.F., H.G., D.M., A.Ho., G.B., I.McN., J.D.B. conducted sample collection; T.E.G., D.E., A.M.P., L.A.L., A.Ha., C.W., C.N., L.Mi., L.N.S., M.J.L., L.Mo., A.S., J.P. performed experiments; G.M., T.E.G., D.D.S., M.E., D.S., B.Y., O.H., F.M. performed data analysis; G.M., D.D.S., F.M. developed the methodology and software; G.M., T.E.G., D.D.S., F.M., I.McN., J.D.B. wrote the manuscript.

Competing Financial Interests Statement

The following authors have a competing interest as defined by Nature Research:

C.G. Personal interest: Roche, AstraZeneca, Tesaro, Clovis, Foundation One, Nucana. Research funding: AstraZeneca, Novartis, Aprea, Nucana, Tesaro. Named co-inventor on five patents (issued: PCT/US2012/040805; pending: PCT/GB2013/053202, 1409479.1, 1409476.7 and 1409478.3)

H.G. Employment: AstraZeneca

I.McN. Personal interest: Clovis Oncology.

J.D.B. Cofounder and shareholder of Inivata Ltd (a cancer genomics company that commercializes ctDNA analysis)

All other authors declare that they have no competing financial or non-financial interests as defined by Nature Research.

E1 1BB ⁹Guy's Hospital, London, SE1 9RT, UK ¹⁰Bristol Cancer Institute, Bristol, BS2 8ED, UK ¹¹City Hospital, Birmingham, B18 7QH, UK ¹²Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK ¹³Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre; Level 5, Research, Oxford Road, Manchester, UK ¹⁴St James's Institute of Oncology, Leeds, LS9 7TF UK ¹⁵The Christie Hospital, Manchester, M20 4BX, UK ¹⁶Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, University of Edinburgh, Edinburgh, EH4 2XR, UK ¹⁷Mount Vernon Cancer Centre, Northwood, HA6 2RN, UK ¹⁸Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, W12 0NN, UK ¹⁹Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK ²⁰Department of Pathology, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK ²¹Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK ²²Centre for Cancer Research, University of Melbourne, VIC 3010 Australia ²³Department of Oncology, University of Cambridge, CB2 0XZ, UK

Abstract

The genomic complexity of profound copy-number aberration has prevented effective molecular stratification of ovarian cancers. To decode this complexity, we derived copy-number signatures from shallow whole genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were validated on 527 independent cases. We show that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration. Copy-number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Measuring signature exposures provides a rational framework to choose combination treatments that target multiple mutational processes.

Introduction

The discrete mutational processes that drive copy-number change in human cancers are not readily identifiable from genome-wide sequence data. This presents a major challenge for the development of precision medicine for cancers that are strongly dominated by copy-number changes, including high-grade serous ovarian (HGSOC), esophageal, non-small-cell lung and triple negative breast cancers¹. These tumors have low frequency of recurrent oncogenic mutations, few recurrent copy number alterations, and highly complex genomic profiles².

HGSOCs are poor prognosis carcinomas with ubiquitous *TP53* mutation³. Despite efforts to discover new molecular subtypes and targeted therapies, overall survival has not improved over two decades⁴. Current genomic stratification is limited to defining homologous recombination-deficient (HRD) tumors^{5–7} with approximately 20% HGSOC cases having a germline or somatic mutation in *BRCA1/2* with smaller contributions from mutation or epigenetic silencing of other HR genes⁸. Classification using gene expression predominantly reflects the tumor microenvironment and is reliable in only a subset of patients^{9–11}.

Detailed genomic analysis using whole genome sequencing has shown frequent loss of *RBI*, *NFI* and *PTEN* by gene breakage events¹² and enrichment of amplification associated fold-back inversions in non-HRD tumors¹³. However, none of these approaches has provided a broad mechanistic understanding of HGSOC, reflecting the challenges of detecting classifiers in extreme genomic complexity.

Recent algorithmic advances have enabled interpretation of complex genomic changes by identifying mutational signatures — genomic patterns that are the imprint of mutagenic processes accumulated over the lifetime of a cancer cell¹⁴. For example, UV exposure or mismatch repair defects induce distinct, detectable single nucleotide variant (SNV) signatures¹⁴. The clinical utility of these signatures has recently been demonstrated through a combination of structural variant (SV) and SNV signatures to improve the prediction of HRD¹⁵. Importantly, these studies show that tumor genomes are shaped by multiple mutational processes and novel computational approaches are needed to identify coexistent signatures. We hypothesized that specific features of copy-number abnormalities could represent the imprints of distinct mutational processes, and developed methods to identify signatures from copy-number features in HGSOC.

Results

Experimental design and data collection

We generated absolute copy number profiles from 253 primary and relapsed HGSOC samples from 132 patients in the BriTROC-1 cohort¹⁶ using low-cost shallow whole-genome sequencing (sWGS; 0.1×) and targeted amplicon sequencing of *TP53* (Supplementary Figure 1). These samples formed the basis of our copy-number signature identification. A subset of 56 of these cases had deep whole-genome sequencing (dWGS) performed for mutation analysis and comparison with sWGS data. Independent data sets for validation included 112 dWGS HGSOC cases from PCAWG¹⁷ and 415 HGSOC cases with SNP array and whole exome sequence from TCGA⁸. Supplementary Figure 1a shows the REMARK diagram for selection of BriTROC-1 patients. Supplementary Figure 1b outlines which samples were used in each analysis across the three cohorts. Clinical data for the BriTROC-1 cohort are summarized in Supplementary Table 1 and Supplementary Figure 2. Detailed information on experimental design is provided in the Life Sciences Reporting Summary.

Identification and validation of copy-number signatures

To identify copy-number (CN) signatures, we computed the genome-wide distributions of six fundamental CN features for each sample: the breakpoint count per 10MB, the copy-number of segments, the difference in CN between adjacent segments, the breakpoint count per chromosome arm, the lengths of oscillating CN segment chains and the size of segments. These features were selected as hallmarks of previously reported genomic aberrations, including breakage-fusion-bridge cycles¹⁸, chromothripsis¹⁹ and tandem duplication^{20,21}.

We applied mixture modelling to separate the copy-number feature distributions from 91 BriTROC-1 samples with high quality CN profiles into mixtures of Poisson or Gaussian

distributions. This resulted in a total of 36 mixture components (Figure 1a). For each sample, the posterior probability of copy-number events arising from these components was computed and summed. These sum-of-posterior vectors were then combined to form a sample-by-component sum-of-posteriors matrix. To identify copy-number signatures, this matrix was subjected to non-negative matrix factorization (NMF)²², a method previously used for deriving SNV signatures¹⁴.

NMF identified seven CN signatures (Figure 1a), as well as their defining features and exposures in each sample. The optimal number of signatures was chosen using a consensus from 1000 initializations of the algorithm and 1000 random permutations of the data combining four model selection measures (Supplementary Figure 3). We found highly similar component weights for the signatures in the two independent cohorts (PCAWG-OV and TCGA), demonstrating the robustness of both the methodology and the copy-number features (Figure 1b, $P < 9e-05$, median $r = 0.86$. Supplementary Table 2), despite a significant difference in exposures to CN signatures 2, 3, 4 and 5 between the cohorts ($P < 0.05$, two-sided Wilcoxon rank sum test, Supplementary Figure 4).

Mutational processes underlying copy-number signatures

The majority of cases analysed exhibited multiple signature exposures suggesting that HGSOC genomes are shaped by more than one mutational process. As our signature analysis reduced this genomic complexity into its constituent components, we were able to link the individual copy-number signatures to their underlying mutational processes. To do this, we used the component weights identified by NMF to determine which pattern of global or local copy-number change defined each signature. For example, for CN signature 1, the highest weights were observed for components representing low numbers of breakpoints per 10MB, long genomic segments and two breaks occurring per chromosome arm (Figure 2a, Supplementary Figure 5). Two breaks per chromosome arm suggested that the mutational process underlying this signature might be breakage-fusion-bridge (BFB) events¹⁸.

To test this hypothesis, we correlated CN signature 1 exposures with mutation data, SNV signatures, and other measures derived from deep WGS and exome sequencing (Figure 2b-e, Supplementary Figures 6, 7, 8 and 9, Supplementary Tables 3, 4, 5, 6, 7 and 8). CN signature 1 was anti-correlated with sequencing estimates of telomere length ($r = -0.32$, $P = 0.009$), consistent with BFB events. In addition, CN signature 1 was positively correlated with amplification-associated fold-back inversion structural variants ($r = 0.36$, $P = 0.02$), which have been strongly implicated in BFB events²³ and have also been associated with inferior survival in HGSOC¹³. CN signature 1 was also enriched in cases with oncogenic RAS signaling, including *NFI* loss and mutated *KRAS* ($p = 5e-06$, Mann-Whitney test), which has previously been shown to induce chromosomal instability as a result of aberrant G2 and mitotic checkpoint controls and missegregation^{24,25}. Taken together, these data provide independent evidence for BFB arising as a result of oncogenic RAS signaling and telomere shortening as the underlying mechanism for CN signature 1.

We applied these approaches to the remaining signatures to identify statistically significant genomic associations using a false discovery rate <0.05 (Figure 2b-e, Figure 3, Supplementary Figures 5, 6, 7, 8 and 9, Supplementary Tables 3, 4, 5, 6, 7 and 8).

CN signature 2 showed frequent breakpoints per 10MB, single changes in copy-number (resulting in 3 copies), chains of oscillating copy-number, and was significantly correlated with tandem duplicator phenotype scores ($r=0.3$, $P=0.004$) and SNV signature 5 ($r=0.26$, $P=0.02$). In addition, this signature was enriched in patients with mutations in *CDK12* ($P=0.02$, Mann-Whitney test, Supplementary Table 6), in keeping with previous studies that have demonstrated large tandem duplication in cases with inactivating *CDK12* mutations²⁶.

CN signature 4 was characterised by high copy-number states (4-8 copies) and predominant copy-number change-points of size 2. This pattern indicates a mutational process of late whole-genome duplication (WGD)²⁷. Significantly increased signature 4 exposure in cases with aberrant PI3K/AKT signaling provided further support for late WGD as oncogenic PIK3CA induces tolerance to genome doubling²⁸ ($P=2e-22$, Mann-Whitney test, mutation of *PIK3CA* or amplification of *AKT*, *EGFR*, *MET*, *FGFR3* and *ERBB2*). Signature 4 was also seen at higher levels in cases with mutations in genes encoding proteins from Toll-like receptor signaling cascades ($P=2e-07$), interleukin signaling pathways ($P=3e-24$) and *CDK12* ($P=0.0009$), as well as those with amplified *CCNE1* ($P=2e-10$) and *MYC* ($P=9e-12$). It was also significantly correlated with telomere length ($r=0.46$, $P=4e-05$).

CN signature 6 showed extremely high copy-number states and high copy-number change-points for small segments interspersed among larger, lower-copy segments. This suggests a mutational process resulting in focal amplification. Increased signature 6 exposure was associated with mutations in genes encoding proteins across diverse pathways, including aberrant G1/S cell cycle checkpoint control (through either amplification of *CCNE1*, *CCND1*, *CDK2*, *CDK4* or *MYC*, deletion/inactivation of *RBI* or mutation in *CDK12*), Toll-like receptor signaling cascades and PI3K/AKT signaling ($P<0.05$). However, as many of these statistical associations are marked by gene amplification, it is difficult to determine whether the copy number states represent causal events or are simply a consequence of focal amplification. Exposure to CN signature 6 was also positively correlated with age at diagnosis ($r=0.31$, $P=6e-12$) and age-related SNV signature 114 ($r=0.43$, $P=3e-06$).

CN signature 5 was significantly associated with predicted chromothriptic-like events using the Shatterproof algorithm²⁹ ($r=0.44$, $P=2e-03$). Chromothripsis is considered rare in HGSOC^{12,27,30}. However, the key component of this signature—the presence of copy-number change points centered at 0.5 copies—suggests that the events are subclonal. This implies that chromothripsis may be an underestimated oncogenic mechanism in HGSOC that could reflect ongoing formation and rupture of micronuclei³¹.

CN signature 3 was characterized by an even distribution of breaks across all chromosomes, and copy number changes from diploid to single copy (LOH). CN signature 3 was significantly enriched in cases with mutations in *BRCA1* and *BRCA2*, and other HR genes including *BARD1*, *PALB2* and *ATR* ($P=0.002$, Mann-Whitney test). It was also correlated with the HRD-related SNV signature 3 ($r=0.32$, $P=0.002$) and anti-correlated with age at

diagnosis and age-related SNV signature 1 ($P < 0.05$). CN signature 3 was also enriched in cases with loss of function mutations in *PTEN* ($P = 0.002$, Mann-Whitney test). Taken together, these data suggest that CN signature 3 is driven by *BRCA1/2*-related HRD mechanisms.

CN signature 7, like CN signature 3, also demonstrated an even distribution of breaks across all chromosomes. By contrast with CN signature 3, single copy-number changes were observed from a tetraploid rather than a diploid state (Figure 3). Although there was correlation with the HRD-related SNV signature 3, there was no enrichment with *BRCA1/2* mutation, suggesting alternative HRD mechanisms as potential mutational processes.

We also investigated relationships between CN signatures. *BRCA1* dysfunction and *CCNE1* amplification have been shown to be mutually exclusive in HGSOC32, and we observed that CN signature 3 (*BRCA1/2*HRD) and CN signature 6 (marked by aberrant G1/S cell cycle checkpoint control) showed mutually exclusive associations (Figure 2b-e). Loss of *BRCA1* and *BRCA2* are early driver events in HGSOC, and to investigate acquisition of additional mutational processes, we studied four BriTROC-1 cases with deleterious germline *BRCA2* mutations and confirmed somatic loss of heterozygosity at *BRCA2* (Figure 4). A diverse and variable number of CN signatures was seen in these cases, including substantial exposures to CN signature 1 (RAS signaling) in three of the four cases.

Copy-number signatures predict overall survival

We next explored the association between individual CN signature exposures and overall survival using a combined dataset of 575 diagnostic samples with clinical outcomes. We trained a multivariate Cox proportional hazards model on 417 cases and tested this on the remaining 158 cases (Figure 5, Supplementary Table 9). CN signature exposure was significantly predictive of survival (Training: $P = 0.002$, log-rank test; stratified by age and cohort; Test: $P = 0.05$, C-index=0.56, 95% CI:0.50-0.62; Entire cohort: $P = 0.002$, log-rank test; stratified by age and cohort). Across the entire cohort, poor outcome was significantly predicted by CN signature 1 ($P = 0.0008$) and CN signature 2 exposures ($P = 0.03$), whilst good outcome was significantly predicted by exposures to CN signatures 3 ($P = 0.05$) and 7 ($P = 0.006$).

Unsupervised hierarchical clustering of samples by signature exposures identified three clusters (Figure 5). Despite showing significant survival differences ($P = 0.004$, log-rank test; stratified by age and cohort), these clusters did not provide any prognostic information in addition to that identified from the Cox proportional hazards model; cluster 2 was dominated by patients with high signature 1 exposures (poor prognosis), cluster 3 showed high signature 3 exposures (good prognosis) and cluster 1 had mixed signature exposures (Supplementary Figure 10).

Copy-number signatures indicate relapse following chemotherapy

Using a generalised linear model, we investigated whether copy-number signatures could be used to predict outcome following chemotherapy across 36 patients from the BriTROC-1 study with paired diagnostic and relapse samples 16. The model showed CN signature 1

exposures at the time of diagnosis to be significantly predictive of platinum-resistant relapse ($P=0.02$, z-test, Supplementary Table 10).

Using the same 36 sample pairs, we also investigated whether chemotherapy treatment changed CN signature exposures. No significant effects on exposures were observed following chemotherapy treatment using a linear model that accounted for signature exposure at time of diagnosis, number of lines of chemotherapy and patient age ($P>0.05$, F-test, Supplementary Table 10). The only variable showing a significant association with exposure at relapse was signature exposure at diagnosis ($P<0.01$, F-test, Supplementary Table 11).

Discussion

Copy-number signatures provide a framework that is able to rederive the major defining elements of HGSOC genomes, including defective HR8, amplification of *CCNE19* and amplification-associated fold-back inversions¹³. In addition, the CN signatures show significant associations with known driver gene mutations in HGSOC and provide the ability to detect novel associations with gene mutations. We derived signatures using inexpensive shallow whole genome sequencing of DNA from core biopsies. These approaches are rapid and cost effective, thus providing a clear path to clinical implementation. Copy-number signatures open new avenues for clinical trial design by highlighting contributions from underlying mutational processes that depend on oncogenic RAS and PI3K/AKT signaling.

We found that almost all patients with HGSOC demonstrated a mixture of signatures indicative of combinations of mutational processes. These results suggest that early *TP53* mutation, the ubiquitous initiating event in HGSOC, may permit multiple mutational processes to co-evolve, potentially simultaneously. Although further work is needed to define the precise timing of signature exposures, early driver events such as *BRCA2* mutation still permit a diverse and variable number of CN signatures in addition to an HRD signature (Figure 4). These additional signature exposures may alter the risk of developing therapeutic resistance, particularly when only a single mutational process such as HRD is targeted.

High exposure to CN signature 3, characterised by *BRCA1/2*-related HRD, is associated with improved overall survival, confirming prior data showing that *BRCA1/2* mutation is associated with long survival in HGSOC^{33,34}. Conversely, high exposure to signature 1, which is characterised by oncogenic RAS signaling (including *NF1*, *KRAS* and *NRAS* mutation), predicts subsequent platinum-resistant relapse and poor survival. This suggests that powerful intrinsic resistance mechanisms are present at the time of diagnosis and can be readily identified using CN signature analysis. This hypothesis is supported by the presence of exposure to CN signature 1 in germline *BRCA2*-mutated cases (Figure 4) as well as our previous work demonstrating the expansion of a resistant subclonal *NF1*-deleted population following chemotherapy treatment in HGSOC³⁵ and poor outcomes in *Nf1*-deleted murine models of HGSOC³⁶. Our CN signature analysis of *BRCA2*-mutated cases also concurs with PCAWG/ICGC data showing that over half (9/16) of *NF1*-mutated cases also harboured mutations in *BRCA1* or *BRCA2*¹². These data suggest a complex interplay between RAS

signaling and HRD. Thus, RAS signaling may be an important target, especially in first line treatment, to prevent emergence of platinum-resistant disease.

We found that CN signature exposures were not significantly altered between diagnosis and disease relapse in 36 sample pairs with a median interval of 30.6 months¹⁶. This suggests that the underlying mutational processes in HGSOV are relatively stable and that genome-wide patterns of copy-number change mainly reflect historic alterations to the genome acquired during tumorigenesis³⁷. Relative invariant genomic changes were also observed in the ARIEL2 trial, where genome-wide loss-of-heterozygosity was used to predict HRD, and only 14.5% (17/117) cases changed LOH status between diagnosis and relapse⁷.

Larger association studies will be required to further refine CN signature definitions and interpretation. The application of our approach to other tumour types is likely to extend the set of signatures beyond the robust core set identified here. Basal-like breast cancers, squamous cell and small cell lung carcinoma, which all have high rates of *TP53* mutation and genomic instability², are promising next targets. Although it is likely that the strong associations have identified the driver mutational processes for CN signatures 1 and 3, functional studies will be required to establish causal links for the remaining signatures. For example, CN signature 6 was significantly associated with multiple mutated pathways, and this association was primarily driven by amplification of target genes. As this signature represented focal amplification events, it is difficult to determine whether amplification of specific genes drives the underlying mutational process or the amplifications emerge as a consequence of strong selection of advantageous phenotypes. Our data does not provide timing information for exposures and there is the real possibility that one mutational process may well drive the emergence of other mutational processes. For example, the association between signature 6 and PI3K signalling is also shared with signature 4.

Other limitations of this work are technical: we integrated data from three sources, using three different pre-processing pipelines, and the ploidy determined by different pipelines can have a significant effect on the derived signatures. For example, high-ploidy CN signature 4 was predominantly found in the sequenced samples that underwent careful manual curation to identify whole-genome duplication events. When extending to larger sample sets, a unified processing strategy with correct ploidy determination is likely to produce improved signature definitions. Another technical limitation is the resolution of copy-number calling from sWGS (limited to 30kb bins) and future application to large cohorts of deeply sequenced samples will be needed to improve the resolution of the CN signatures.

Efforts to identify discrete, clinically relevant subtypes of disease have been successful in many cancer types^{38–40}. However, HGSOV lacks clinically-relevant patient stratification, which is reflected in continued poor survival. We show that HGSOV genomes are shaped by multiple mutational processes that preclude simple subtyping. Thus, our results suggest that HGSOV is a continuum of genomes. By dissecting the mutational forces shaping HGSOV genomes, our study paves the way to understanding extreme genomic complexity, as well as revealing the evolution of tumors as they relapse and acquire resistance to chemotherapy.

Online Methods

Patients and samples

The BriTROC-1 study has been described previously¹⁶. Characteristics of the 142 patients included in this study are given in Supplementary Table 1. The study is sponsored by NHS Greater Glasgow and Clyde and ethics/IRB approval was given by Cambridge Central Research Ethics Committee (Reference 12/EE/0349). The study enrolled patients with recurrent ovarian high-grade serous or grade 3 endometrioid carcinoma who had relapsed following at least one line of platinum-based chemotherapy and whose disease was amenable either to image-guided biopsy or secondary debulking surgery. At study entry, patients were classified as having either platinum-sensitive relapse (i.e. relapse six months or more following last platinum chemotherapy) or platinum-resistant relapse (i.e. relapse less than six months following prior platinum chemotherapy) (Supplementary Figure 2). All patients provided written informed consent. Access to archival diagnostic formalin-fixed tumor was also required. Survival was calculated from the date of enrolment to the date of death or the last clinical assessment, with data cutoff at 1 December 2016. At subsequent relapse or progression after chemotherapy following study entry, patients could optionally have a second biopsy under separate consent.

DNA was extracted from 300 samples of 142 patients - 158 methanol-fixed relapse biopsies and 142 FFPE archival diagnostic tissues. Germline DNA was extracted from blood samples of 137 patients.

Tagged-amplicon sequencing

Mutation screening of *TP53*, *PTEN*, *EGFR*, *PIK3CA*, *KRAS* and *BRAF* was performed on all 300 samples using tagged-amplicon sequencing as previously described¹⁶. DNA extracted from blood was analyzed by tagged-amplicon sequencing for *BRCA1* and *BRCA2* germline mutations.

Shallow whole genome sequencing (sWGS)

Libraries for sWGS were prepared from 100ng DNA using modified TruSeq Nano DNA LT Sample Prep Kit (Illumina) protocol⁴¹. Quality and quantity of the libraries were assessed with DNA-7500 kit on 2100 Bioanalyzer (Agilent Technologies) and with Kapa Library Quantification kit (Kapa Biosystems) according to the manufacturer's protocols. Sixteen to twenty barcoded libraries were pooled together in equimolar amounts and each pool was sequenced on HiSeq4000 in SE-50bp mode.

Prior to sequencing we estimated the required sequencing depth by adapting calculations made in previous work that explored the relationship between sequencing depth (reads per sample) and copy number calling accuracy⁴². Based on these analyses, we devised a power calculator for sWGS copy number analysis (see ^{URL} ¹, described in 43). We estimated that with an average ploidy of 3 and purity of 0.65, a sequencing depth of at least 2.7 million reads is required to detect single, clonal copy-number changes (minimum 60kb) at 90%

¹https://gmacintyre.shinyapps.io/sWGS_power/

power and alpha 0.05. After analysis we determined that BritROC 3-star samples had an average purity of 0.66, ploidy of 2.7, and were sequenced to an average depth of 8.6 million reads. This allowed us to detect single copy-number changes with 90% power, and alpha 0.05 down to subclonal frequencies of 55%.

Deep whole genome sequencing

Deep whole-genome sequencing was performed on 56 tumors with confirmed *TP53* mutations and matched normal samples, of which 48 passed quality control. Libraries were constructed with ~350-bp insert length using the TruSeq Nano DNA Library prep kit (Illumina) and sequenced on an Illumina HiSeq X Ten System in paired-end 150-bp reads mode. The average depth was 60× (range 40-101×) in tumors and 40× (range 24-73×) in matched blood samples.

Variant calling

Read alignment and variant calling of tagged-amplicon sequencing data were processed as described⁴¹. Deep WGS samples were processed with bcbio-nextgen⁴⁴ using Ensemble somatic variants called by two methods out of VarDict⁴⁵, Varscan⁴⁶ and FreeBayes⁴⁷. Somatic SNV calls were further filtered based on mapping quality, base quality, position in read, and strand bias as described⁴⁰. In addition, the blacklisted SNVs from the Sanger Cancer Genomics Project pipeline derived from a panel of unmatched normal samples were used for filtering⁴⁸.

Data download

PCAWG-OV—Consensus SNVs and INDELs (October 2016 release), consensus structural variants (v 1.6), consensus copy-number calls (January 2017 release), donor clinical (August 2016 v7-2) and donor histology information (August 2016 v7) for 112 ovarian cancer samples were downloaded from the PCAWG data portal. ABSOLUTE⁴⁹ copy-number calls were used for analysis.

TCGA—ABSOLUTE⁴⁹ copy-number profiles from Zack et al²⁷ for 415 ovarian cancer TCGA samples were downloaded from Synapse⁵⁰. SNVs for these samples were downloaded from the Broad Institute TCGA Genome Data Analysis Center (Broad Institute TCGA Genome Data Analysis Center: Firehose stddata__2016_01_28 run. doi:10.7908/C11G0KM9, Broad Institute of MIT and Harvard). Donor clinical data were downloaded from the TCGA data portal.

Absolute copy-number calling from sWGS

Segmentation—sWGS reads were aligned and relative copy-number called as described⁴¹. After inspection of the *TP53* mutation status and relative copy-number profiles of the 300 sequenced BriTROC-1 samples, 47 were excluded from downstream analysis for the following reasons: low purity (24), mislabeled (7), pathology re-review revealed sample was not HGSOC (3), no detectable *TP53* mutation (13). Of the 253 BriTROC-1 samples analysed, 111 were FFPE-fixed. Fifty seven out of 253 showed an over segmentation artefact

(likely due to fixation). A more strict segmentation was subsequently applied to these samples to yield a usable copy-number profile.

Absolute copy number—We combined relative copy-number profiles generated by QDNAseq42 with mutant allele frequency identified using tagged amplicon sequencing in a probabilistic graphical modelling approach to infer absolute copy-number profiles. Using Expectation-Maximisation, the model generated a posterior over a range of *TP53* copy-number states, using the *TP53* mutant allele frequency to estimate purity for each state. The *TP53* copy-number state that provided the highest likelihood of generating a clonal absolute copy-number profile was used to determine the final absolute copy-number profile. To test the validity of this approach, we compared purity and ploidy estimates derived from sWGS to those derived from 60× WGS using the Battenberg algorithm for copy-number calling⁵¹. Pearson correlation coefficients were computed for both ploidy and purity estimates using 34 3-star (see Quality rating) BriTROC-1 samples with matched sWGS and WGS (Supplementary Figure 11).

Quality rating—Following absolute copy-number fitting, samples were rated using a 1-3 star system. 1-star samples (n=54) showed a noisy copy-number profile and were considered likely to have incorrect segments and missing calls. These were excluded from further analysis. 2-star samples (n=52) showed a reasonable copy-number profile with only a small number of miscalled segments. These samples were used (with caution) for some subsequent analyses. 3-star samples (n=147) showed a high-quality copy-number profile that was used in all downstream analyses. The maximum star rating observed per patient was 1-star in 15 patients, 2-star in 26, and 3-star in 91 patients. Seventy-two out of 111 FFPE-fixed samples (64%) were amenable to signature analysis. This is consistent with typical sequencing success rates for archival material⁵².

Copy-number signature identification

Preprocessing—91 3-star BriTROC-1 absolute copy-number profiles were summarized using the genome-wide distribution of six different features (outlined in Figure 1):

1. Segment size - the length of each genome segment;
2. Breakpoint count per 10MB - the number of genome breaks appearing in 10MB sliding windows across the genome;
3. Change-point copy-number - the absolute difference in CN between adjacent segments across the genome;
4. Segment copy-number - the observed absolute copy-number state of each segment;
5. Breakpoint count per chromosome arm - the number of breaks occurring per chromosome arm;
6. Length of segments with oscillating copy-number - a traversal of the genome counting the number of contiguous CN segments alternating between two copy-number states, rounded to the nearest integer copy-number state.

Mixture modelling—For each of the feature density distributions, we applied mixture modelling to identify its distinct components. For distributions representing segment-size, change-point copy-number, and segment copy-number we employed mixtures of Gaussians. For distributions representing breakpoint count per 10MB, length of segments with oscillating copy-number, and breakpoint count per chromosome arm we employed mixtures of Poissons. Mixture modelling was performed using the FlexMix V2 package in R53. The algorithm was run for each distribution with the number of components ranging from 2-10. The optimal number of components was selected as the run showing the lowest Bayesian Information Criterion, resulting in a total of 36 components (see Figure 1 and Supplementary Table 3 for breakdown). Next, for each copy-number event, we computed the posterior probability of belonging to a component. For each sample, these posterior event vectors were summed resulting in a sum-of-posterior probabilities vector. All sum-of-posterior vectors were combined in a patient-by-component sum-of-posterior probabilities matrix.

Signature identification—The NMF Package in R54, with the Brunet algorithm specification⁵⁵ was used to deconvolute the patient-by-component sum-of-posteriors matrix into a patient-by-signature matrix and a signature-by-component matrix. A signature search interval of 3-12 was used, running the NMF 1000 times with different random seeds for each signature number. As provided by the NMF Package⁵⁴, the cophenetic, dispersion, silhouette, and sparseness coefficients were computed for the signature-by-component matrix (basis), patient-by-signature matrix (coefficients) and connectivity matrix (consensus, representing patients clustered by their dominant signature across the 1000 runs). 1000 random shuffles of the input matrix were performed to get a null estimate of each of the scores (Supplementary Figure 3). We sought the minimum signature number that yielded stability in the cophenetic, dispersion and silhouette coefficients, and that yielded the maximum sparsity which could be achieved without exceeding that which was observed in the randomly permuted matrices. As a result, 7 signatures were deemed optimal under these constraints and were chosen for the remaining analysis.

Signature assignment—For the remaining 26 2-star patient samples, and the 82 secondary patient samples (from patients with 2- or 3-star profiles from additional tumor samples), the LCD function in the YAPSA package in Bioconductor⁵⁶ was used to assign signature exposures.

Copy-number signature validation

The signature identification procedure described above was applied to copy-number profiles from two independent datasets: 112 whole-genome sequenced (approximately 40×) HGSOc samples processed as part of ICGC Pan-Cancer Analysis of Whole Genomes Project¹⁷, (denoted here as PCAWG-OV) and 415 SNParray profiling of HGSOc cases as part of TCGA²⁷. The number of signatures was fixed at 7 for matrix decomposition with NMF. Pearson correlation was computed between the BriTROC-1 signature-by-component weight matrix and each of the PCAWG-OV and TCGA signature-by-component matrices, signature by signature (Supplementary Table 2).

Association of copy-number signature exposures with other features

Association of signature exposures with other features was performed using one of two procedures: for a continuous association variable, correlation was performed; for a binary association variable, patients were divided into two groups and a Mann-Whitney test was performed to test for differences in signature exposure medians between the two groups. A more detailed explanation of each of these association calculations is given below. (Note: of the 48 deep WGS BriTROC-1 samples that passed QC, only 44 had matched 2- and 3-star sWGS copy-number profiles. As signature exposures from sWGS were used for BriTROC-1 sample associations, only these 44 samples could be used).

Age at diagnosis—Patient age at diagnosis for 112 PCAWG-OV samples and 415 TCGA samples was used to compute Pearson correlation with signature exposures.

Amplification associated fold-back inversions—For 111 PCAWG-OV samples, the fraction of amplification associated fold-back inversion events per sample was calculated as the proportion of head-to-head inversions (h2hINVs) within a 100kb window amplified region (copy number ≥ 5) relative to the total number of SV calls per sample. 94 samples had at least 1 h2hINV event out of which 58 had h2hINV events in amplified regions. On average they accounted for 4% of SV calls. As these are rare events, only samples showing a non-zero fraction of fold-back inversions (n=67) were used to compute Pearson correlation with signature exposures.

Telomere length—Telomere lengths of 44 deep WGS tumor samples from the BriTROC-1 cohort were estimated using the Telomerecat algorithm⁵⁷. Telomere length estimates ranged from 1.5kb - 11kb with an average of 4kb. Correlation between telomere length and copy-number signature exposures was calculated with age and tumor purity as covariates using the ppcor package in R⁵⁸.

Chromothripsis—Copy-number and translocation information from 111 PCAWG-OV samples were used to detect chromothripsis-like events using the Shatterproof software with default parameters²⁹. Shatterproof, a state-of-the-art software, incorporates a wide range of hallmarks of chromothripsis in its detection algorithm as a precise definition of chromothripsis remains elusive. Govind et al. recommend a threshold of 0.37 based on their observations that normal samples produced a low number of calls with low scores (maximum 0.37) while prostate, colorectal and small cell lung cancer samples that were known to have chromothriptic events, produced the highest scores²⁹. Previous studies have reported a low incidence of chromothriptic events in HGSOc^{12,27,30}. The number of calls per sample in the PCAWG-OV samples ranged from 5 to 47 with an average of 23. The score per call ranged from 0.15-0.62 with a median of 0.38. Therefore, a conservative threshold was set at the 95th percentile of our distribution of scores to minimise false positives and calls with scores greater than 0.48 were used to obtain a count of chromothriptic events per sample. As chromothriptic events are rare in HGSOc, only samples showing a non-zero number of events (n=61) were used to compute Pearson correlation with signature exposures. Of 61 samples with scores above the threshold, 49

(80.3%) had 1-2 events, 11 samples (18%) had 3-6 events and 1 sample (1.6%) had 10 events.

Tandem duplicator phenotypes—Tandem duplicator phenotype (TDP) scores were calculated for 111 PCAWG-OV samples using the method described in Menghi et al²¹. The number of duplication events per chromosome normalized by chromosome length per sample was used to calculate a score relative to the expected number of duplication events per chromosome per sample. The scores ranged from -1.11 to 0.53 with an average score of 0.02.

Mutational signatures—Motif matrices were extracted using the SomaticSignatures R package⁵⁹ and the weights of all known COSMIC signatures were determined using the deconstructSigs R package⁶⁰ for 44 deep WGS BriTROC-1 samples and 109 PCAWG-OV samples. SNV signatures showing an exposure >0 for at least one sample were retained. The `rcorr` function in the Hmisc R package⁶¹ was used to calculate the correlation matrix between the remaining SNV and CN signature exposures.

The significance of all observed correlations was estimated from a t-distribution where the null hypothesis was that the true correlation was 0. All reported p-values have been adjusted for multiple testing with Benjamini & Hochberg (BH) method⁶². Comparison plots can be found in Supplementary Figure 6.

Mutated pathways—A combined set of 479 samples (44 deep WGS BriTROC-1, 112 PCAWG-OV and 323 TCGA) showing at least one driver mutation was used for mutated pathway enrichment analysis. We focused on 765 driver genes reported by Cancer Genome Interpreter (CGI)⁶³. SNVs, INDELS, amplifications (CN>5) or deletions (CN<0.4) affecting these genes were considered *bona fide* driver mutations if CGI predicted them as TIER1 or TIER2 (Supplementary Tables 4 and 5, see ^{URL}², run date: 2018-01-13). 320 of the 765 genes were mutated in a least one case. These genes were used to test for enriched pathways in the Reactome database using the ReactomePA R package⁶⁴ with a p-value cutoff of 0.05 and q-value cutoff of 0.05. Pathways mutated in at least 5% of the cohort (n = 24) were retained. For each pathway, patients were split into two groups: those with mutated genes in the pathways, and those with wild-type genes in the pathways. A one-sided Mann-Whitney was carried out for each signature to determine if the exposure was significantly higher in mutated cases versus wild-type cases. After multiple testing correction using the Benjamini & Hochberg method (thresholding the p-value <0.005 and the median difference in exposures = 0.1), 186 pathways were significantly enriched. Visual inspection revealed significant redundancy in the list and 9 representative pathways were manually selected as a final output (Supplementary Table 6).

Mutated genes—A combined set of 479 samples (44 deep WGS BriTROC-1, 112 PCAWG-OV and 323 TCGA) was used test if signature exposures were significantly higher in cases with mutated driver genes, including *NFI*, *PTEN*, *BRCA1*, *BRCA2*, *PIK3CA*, *MYC* and *CDK12*. Patients were split into two groups: those with the mutated gene and

²<https://www.cancergenomeinterpreter.org/home>

those with wild-type genes. A one-sided Mann-Whitney was carried out for each signature to determine if the exposure was significantly higher in mutated cases versus wild-type cases. After multiple testing correction using the Benjamini & Hochberg method (thresholding the p-value <0.05 and the median difference in exposures = 0.08), 10 gene/signature combinations were significantly enriched (Supplementary Table 6).

Survival analysis

Censoring and truncation—Overall survival in BriTROC-1 patients was calculated from the date of enrolment to the date of death or the last documented clinical assessment, with data cutoff at 1 December 2016. As the BriTROC-1 study only enrolled patients with relapsed disease, left truncation was used in the survival analysis. In addition, cases where the patient was not deceased were right censored. Survival data for the PCAWG-OV and TCGA cohorts were right censored as required (left truncation was not necessary). The combined samples were split into training (100% BriTROC-1, 70% PCAWG-OV and 70% TCGA = 417) and test (30% PCAWG-OV and 30% TCGA = 158) cohorts. All of the BriTROC-1 samples were used in the training set to avoid issues calculating prediction performance on left-truncated data.

Cox regression—As the signature exposures for a given sample summed to 1, it was necessary to select one normalizing signature to perform regression. Signature 5 was chosen as it showed the lowest variability across the cohorts. To avoid division errors all 0 signature exposures were converted to 0.02. The remaining signature exposures were normalized taking the log ratio of their exposure to signature 5's exposure. A Cox proportional hazards model was fitted on the training set, with the signature exposures as covariates, stratified by cohort (BriTROC-1, PCAWG-OV:AU, PCAWG-OV:US, TCGA) and age (<39; 40:44; 45:49; 50:54; 55:59; 60:64; 65:69; 70:74; 75:79; >80), using the survival package in Bioconductor⁶⁵. After fitting, the model was used to predict risk in the test set and performance was assessed using the concordance index calculation in the survcomp package in Bioconductor⁴⁷. A final Cox regression was performed using all data for reporting of hazard ratios and p-values.

Unsupervised clustering of patients using signature exposures

Hierarchical clustering of the exposure vectors of the 575 samples used in the survival analysis was performed using the NbClust⁶⁶ package in R. The optimal number of clusters was 3 as determined by a consensus voting approach across 23 metrics for choosing the optimal numbers of clusters. 12/23 metrics reported 3 clusters as the optimal number. A Cox proportional hazards model was fitted using the cluster labels as covariates, stratified by cohort (BriTROC-1, PCAWG-OV:AU, PCAWG-OV:US, TCGA) and age (<39; 40:44; 45:49; 50:54; 55:59; 60:64; 65:69; 70:74; 75:79; >80), using the survival package in Bioconductor⁶⁵.

Analysis of copy-number signature changes during treatment

Thirty-six BriTROC-1 cases with matched diagnosis and relapse samples were used to investigate the effects of treatment on signature exposures. A linear model was fitted to test for treatment effects with exposure at relapse as the dependent variable and exposure at

diagnosis, age at diagnosis, number of lines of chemotherapy, and days between diagnosis and relapse as independent variables. Prior to fitting, age at diagnosis was centered and exposures transformed by $\log(x+0.1)$ to ensure normality. Fitting was done using the $lm()$ function in R.

To test whether signature exposures at diagnosis were predictive of platinum sensitivity, a generalized linear model with Binomial error was fitted using type of relapse (platinum-sensitive or platinum-resistant) as the dependent variable and exposure at diagnosis and age at diagnosis as independent variables.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The BriTROC-1 study was funded by Ovarian Cancer Action (to IMcN and JDB, grant number 006). We would like to acknowledge funding and support from Cancer Research UK (grant numbers A15973, A15601, A18072, A17197, A19274 and A19694), the Universities of Cambridge and Glasgow, National Institute for Health Research Cambridge and Imperial Biomedical Research Centres, National Cancer Research Network, the Experimental Cancer Medicine Centres at participating sites, the Beatson Endowment Fund and Hutchison Whampoa Limited. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank the Biorepository, Bioinformatics, Histopathology and Genomics Core Facilities of the Cancer Research UK Cambridge Institute and the Pathology Core at the Cancer Research UK Beatson Institute for technical support. We would like to thank members of PCAWG Evolution and Heterogeneity Working Group for the consensus copy-number analysis, PCAWG Structural Variation Working Group for the consensus structural variants and PCAWG Technical Working Group for annotating driver mutations in the 112 PCAWG-OV samples.

References

1. Ciriello G, et al. Emerging landscape of oncogenic signatures across human cancers. *Nat Genet.* 2013; 45:1127–33. [PubMed: 24071851]
2. Hoadley KA, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell.* 2014; 158:929–44. [PubMed: 25109877]
3. Ahmed AA, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *J Pathol.* 2010; 221:49–56. [PubMed: 20229506]
4. Vaughan S, et al. Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer.* 2011; 11:719–725. [PubMed: 21941283]
5. Fong PC, et al. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. *J Clin Oncol.* 2010; 28:2512–2519. [PubMed: 20406929]
6. Gelmon KA, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011; 12:852–861. [PubMed: 21862407]
7. Swisher EM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2017; 18:75–87. [PubMed: 27908594]
8. TCGA. Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011; 474:609–615. [PubMed: 21720365]
9. Etemadmoghadam D, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. *Clin Cancer Res.* 2009; 15:1417–1427. [PubMed: 19193619]
10. Verhaak RG, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *J Clin Invest.* 2013; 123:517–25. [PubMed: 23257362]

11. Chen GM, et al. Consensus on Molecular Subtypes of Ovarian Cancer. *bioRxiv*. 2017
12. Patch A-M, et al. Whole-genome characterization of chemoresistant ovarian cancer. *Nature*. 2015; 521:489–494. [PubMed: 26017449]
13. Wang YK, et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. *Nat Genet*. 2017; 49:856–865. [PubMed: 28436987]
14. Alexandrov LB, et al. Signatures of mutational processes in human cancer. *Nature*. 2013; 500:415–21. [PubMed: 23945592]
15. Nik-Zainal S, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*. 2016; 534:47–54. [PubMed: 27135926]
16. Goranova T, et al. Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. *Br J Cancer*. 2017; 116:1294–1301. [PubMed: 28359078]
17. Campbell PJ, et al. Pan-cancer analysis of whole genomes. *bioRxiv*. 2017
18. Murnane JP. Telomere dysfunction and chromosome instability. *Mutat Res*. 2012; 730:28–36. [PubMed: 21575645]
19. Korbelt JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. *Cell*. 2013; 152:1226–36. [PubMed: 23498933]
20. Ng CK, et al. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. *J Pathol*. 2012; 226:703–12. [PubMed: 22183581]
21. Menghi F, et al. The tandem duplicator phenotype as a distinct genomic configuration in cancer. *Proc Natl Acad Sci U S A*. 2016; 113:E2373–82. [PubMed: 27071093]
22. Lee M, et al. Comparative analysis of whole genome sequencing-based telomere length measurement techniques. *Methods*. 2017; 114:4–15. [PubMed: 27565742]
23. Zakov S, Kinsella M, Bafna V. An algorithmic approach for breakage–fusion–bridge detection in tumor genomes. *Proc Natl Acad Sci U S A*. 2013; 110:5546–51. [PubMed: 23503850]
24. Knauf JA, et al. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. *J Biol Chem*. 2006; 281:3800–9. [PubMed: 16316983]
25. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ. MAPK mediates RAS-induced chromosome instability. *J Biol Chem*. 1999; 274:38083–90. [PubMed: 10608877]
26. Popova T, et al. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications. *Cancer Res*. 2016; 76:1882–91. [PubMed: 26787835]
27. Zack TI, et al. Pan-cancer patterns of somatic copy number alteration. *Nat Genet*. 2013; 45:1134–40. [PubMed: 24071852]
28. Berenjano IM, et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. *Nat Commun*. 2017; 8:1773. [PubMed: 29170395]
29. Govind SK, et al. ShatterProof: operational detection and quantification of chromothripsis. *BMC Bioinformatics*. 2014; 15:78. [PubMed: 24646301]
30. Malhotra A, et al. Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms. *Genome Res*. 2013; 23:762–76. [PubMed: 23410887]
31. Bakhoun SF, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. *Nature*. 2018; 553:467–472. [PubMed: 29342134]
32. Etemadmoghadam D, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. *Proc Natl Acad Sci U S A*. 2013; 110:19489–94. [PubMed: 24218601]
33. Candido Dos Reis FJ, et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clin Cancer Res*. 2015; 21:652–7. [PubMed: 25398451]
34. Norquist BM, et al. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. *Clin Cancer Res*. 2018; 24:777–783. [PubMed: 29191972]

35. Schwarz RF, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. *PLoS Med.* 2015; 12:e1001789. [PubMed: 25710373]
36. Walton JB, et al. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting *Brcal*, *Pten* and *Nf1*, and correlation with platinum sensitivity. *Scientific Reports.* 2017; 7:16827. [PubMed: 29203787]
37. Gerstung M, et al. The evolutionary history of 2,658 cancers. *bioRxiv.* 2017
38. Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature.* 2012; 486:346–52. [PubMed: 22522925]
39. Kandath C, et al. Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013; 497:67–73. [PubMed: 23636398]
40. Secrier M, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. *Nat Genet.* 2016; 48:1131–41. [PubMed: 27595477]
41. Piskorz AM, et al. Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. *Ann Oncol.* 2016; 27:532–539. [PubMed: 26681675]
42. Scheinin I, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. *Genome Res.* 2014; 24:2022–32. [PubMed: 25236618]
43. Macintyre G, Ylstra B, Brenton JD. Sequencing Structural Variants in Cancer for Precision Therapeutics. *Trends Genet.* 2016; 32:530–42. [PubMed: 27478068]
44. *bcio-nextgen.* (2017).
45. Lai Z, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. *Nucleic Acids Res.* 2016; 44:e108. [PubMed: 27060149]
46. Koboldt DC, et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. *Bioinformatics.* 2009; 25:2283–5. [PubMed: 19542151]
47. Garrison E, M G. Haplotype-based variant detection from short-read sequencing. *arXiv.* 2012
48. Jones D, et al. *cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data.* *Curr Protoc Bioinformatics.* 2016; 56:15 10 1–15 10 18.
49. Carter SL, et al. Absolute quantification of somatic DNA alterations in human cancer. *Nat Biotechnol.* 2012; 30:413–21. [PubMed: 22544022]
50. Schumacher S. *pancan12_absolute.segtab.txt.* 2015
51. Van Loo P, et al. Allele-specific copy number analysis of tumors. *Proc Natl Acad Sci U S A.* 2010; 107:16910–5. [PubMed: 20837533]
52. Al-Kateb H, Nguyen TT, Steger-May K, Pfeifer JD. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). *Mol Oncol.* 2015; 9:1737–43. [PubMed: 26071350]
53. Grün B, Leisch F. FlexMix Version 2: Finite Mixtures with Concomitant Variables and Varying and Constant Parameters. *J Stat Soft.* 2008; 28:35.
54. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. *BMC Bioinformatics.* 2010; 11:367. [PubMed: 20598126]
55. Brunet J-P, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. *Proc Natl Acad Sci U S A.* 2004; 101:4164–4169. [PubMed: 15016911]
56. Huebschmann D, Gu Z, Schlesner M. YAPSA: Yet Another Package for Signature Analysis. R package version 1.2.0. 2015
57. Farmery JHS, Mike L, Lynch Andy G. Telomerecat: A Ploidy-Agnostic Method For Estimating Telomere Length From Whole Genome Sequencing Data. *bioRxiv.* 2017
58. Kim S. *ppcor: Partial and Semi-Partial (Part) Correlation.* 2015
59. Gehrung JS, Fischer B, Lawrence M, Huber W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. *Bioinformatics.* 2015; 31:3673–5. [PubMed: 26163694]
60. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome Biol.* 2016; 17:31. [PubMed: 26899170]
61. Harrell FE. *Hmisc: Harrell Miscellaneous.* R package version 4.0-0. 2016

62. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)*. 1995; 57:289–300.
63. Tamborero D, et al. Cancer Genome Interpreter Annotates The Biological And Clinical Relevance Of Tumor Alterations. *bioRxiv*. 2017
64. Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. *Mol Biosyst*. 2016; 12:477–9. [PubMed: 26661513]
65. Therneau TM, Grambsch Patricia M. *Modeling Survival Data: Extending the Cox Model*. Springer; New York: 2000.
66. Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set. *J Stat Soft*. 2014; 61:36.




Figure 1. Copy-number signature identification from shallow whole genome sequence data and validation in independent cohorts

a. Step 1: Absolute copy-numbers are derived from sWGS data; Step 2: genome-wide distributions of six fundamental copy-number features are computed; Step 3: Gaussian or Poisson mixture models (depending on data type) are fitted to each distribution and the optimal number of components is determined (ranging from 3–10); Step 4: the data are represented as a matrix with 36 mixture component counts per tumor. Step 5: Non-negative

matrix factorization is applied to the components-by-tumor matrix to derive the tumor-by-signature matrix and the signature-by-components matrix.

b. Heat maps show component weights for copy number signatures in two independent cohorts of HGSOc samples profiled using WGS and SNP array. Correlation coefficients are provided in Supplementary Table 2.




Figure 2. Linking copy-number signatures with mutational processes

a Component weights for copy number signature 1. Barplots (upper panel) are grouped by copy number feature and show weights for each of the 36 components. The middle panel shows the mixture model distributions which are shaded by the component weight - solid colours have a high weight and transparent have low weight (contrasting colours are randomly assigned). Lower panel shows genome-wide distribution (histogram or density) of each copy number feature, across the BriTROC-1 cohort, with coloured plots indicating

important distributions (> 0.1 component weight). (Note: similar plots for other CN signatures are shown in Figure 3 and Supplementary Figure 5).

b Associations between CN signature exposures and other features. Purple indicates positive correlation and orange negative correlation (see also Supplementary Figure 6). Numbers at the right of the panel indicate cases included in each analysis. Only significant correlations are shown ($P < 0.05$).

c Associations between CN signature exposures and SNV signatures. Purple indicates positive correlation and orange negative correlation (see also Supplementary Figure 6). The number at the right of the panel indicates cases included in the analysis.

d and e Difference in CN signature exposures between cases with mutations in specific genes (**d**) and mutated/wildtype reactome pathways (**e**). The absolute difference in mean signature exposures was calculated for cases with and without mutations. Colors in filled circles indicate extent of difference. Only differences with FDR $P < 0.05$ (Mann-Whitney test) are shown (see also Supplementary Figure 7).

Numbers at the right of the panel indicate cases with mutations (SNVs, amplifications or deletions) in each gene/pathway.





Figure 3. The seven copy-number signatures in HGSOC

Description of the defining component weights, key associations and proposed mechanisms for the seven copy number signatures.

*only the top three mutated genes for each of the pathways associated with CN signatures 4, 6 and 7 are shown (the list of all significant genes is provided in Supplementary Tables 7 and 8).



BRCA2 germline mutation carriers + somatic LOH (n=4)

Figure 4. CN signature exposures of four BriTROC-1 patients with germline *BRCA2* mutations and somatic loss of heterozygosity

Stacked bar plots show copy-number signature exposures for four BriTROC-1 cases with pathogenic germline *BRCA2* mutations and confirmed somatic loss of heterozygosity (LOH) at the *BRCA2* locus.




Figure 5. Association of survival with copy-number signatures

Upper panel: Stacked barplots show CN signature exposures for each patient. Patients were ranked by risk of death estimated by a multivariate Cox proportional hazards model stratified by age and cohort, with CN signature exposures as covariates.

Middle panel: The matrix indicates group for each patient assigned by unsupervised clustering of CN signature 1, 2, 3 and 7 exposures (see also Supplementary Figure 10).

Lower panel: Linear fit of signature exposures ordered by risk predicted by the Cox proportional hazards model.